SubHero Banner

Uloric® (febuxostat) – Safety communication and updated indication

February 21, 2019 - The FDA announced that there is an increased risk of death with Uloric (febuxostat) use compared to allopurinol. This conclusion was based on an in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with Uloric.

Download PDF